$NTRA

Chapman Rowan E sold $643K of NTRA

Chapman Rowan E sold 2,964 shares of Natera, Inc. (NTRA) at $216.78 ($0.64M total) on 2026-06-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Chapman Rowan E
Published Jun 18, 2026, 1:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 18, 2026, 1:35 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Neutral
high confidence
Mentioned
$NTRA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

This is a disclosed ownership change, but the 10b5-1 pre-arrangement lowers the informational content versus an unplanned sale. Traders may treat it as sentiment/positioning noise rather than a fundamental catalyst.

02

Market read

A director’s 10b5-1 sale is disclosed; potential short-term sentiment impact, but limited expected fundamental effect.

03

What to watch

The article provides only the sale details; it does not indicate whether other insiders bought, whether there were concurrent operational updates, or whether the plan size/frequency signals anything beyond routine selling.

Relevance 4/10Novelty 5/10Timing: Filed 2026-06-17 for a sale executed 2026-06-16

Background

The article is an SEC Form 4 insider transaction disclosure for Natera, Inc., showing a director’s open-market sale executed under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$NTRANeutralHigh confidence
Context

Natera director Chapman Rowan E sold 2,964 shares in an open-market transaction on 2026-06-16 at $216.78/share under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely short-lived unless accompanied by other new catalysts.

Evidence & confidence

The filing is a Form 4 insider sale with explicit 10b5-1 pre-arrangement, reducing interpretability as new negative information.

Market effects

Minimal; single-company insider sale does not reset sector expectations.

None indicated.

None indicated.

Counterpoint

10b5-1 sales can be purely liquidity-driven; the market may overreact to the headline without any change in company fundamentals.

Key entities

  • Natera, Inc.

    Issuer of the Form 4 insider transaction; director Chapman Rowan E sold shares under a 10b5-1 plan.

  • Chapman Rowan E

    Director who executed the open-market sale of 2,964 shares on 2026-06-16.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMedAI 8/10

Natera, Inc.: Signatera Genome with Phased and Structural Variants Highlighted in ESMO Presidential Symposium, Supporting the Critical Role of MRD-Guided Treatment in Bladder Cancer

Natera (NTRA) presented data from the ESMO Congress 2026, showcasing its Signatera assay in 25 abstracts, including 9 oral presentations. The VOLGA trial in bladder cancer showed that Signatera ctDNA dynamics predicted event-free survival, with persistently negative patients having a 24-month EFS rate of 91%. Additional studies in lung, endometrial, and breast cancer were also highlighted, demonstrating the potential of ctDNA testing in guiding treatment decisions.

$NTRAMed

Natera technology featured in 25 abstracts at ESMO congress

Natera Inc. (NTRA) presented cancer study results at the ESMO Congress 2026, with its technology featured in 25 abstracts. Key findings included high event-free survival rates in bladder cancer, high ctDNA detection in lung cancer, and predictive value in endometrial cancer. Studies also covered colorectal and gastroesophageal cancers.

$NTRALow

Natera, Inc. (NTRA) ctDNA Dynamics Predict EFS in MIBC

Natera (NTRA) reported phase III VOLGA trial data showing Signatera ctDNA dynamics predict event-free survival in MIBC, with 24-month EFS rates of 91% for persistently negative, 81% for cleared pre-surgery, and 55% for persistently positive. The company noted this as late-cycle validation for Signatera's role in MRD for bladder cancer.

$NTRAMed

Natera stock price target raised to $430 by BTIG on revenue outlook

BTIG raised its price target on Natera (NTRA) to $430 from $320, citing strong revenue growth expectations. The firm anticipates a 7% revenue beat in Q3 and projects 318,000 Signatera tests, up 57% YoY. Natera's stock is up 77% YTD and 111% over the past year, but is considered overvalued by InvestingPro. Recent Q2 revenue of $753M exceeded expectations, and multiple analysts have raised price targets.